INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Observational study / 2020

Regular intake of glucosamine/chondroitin was linked to lower all-cause and CVD mortality in a national cohort of US adults.

Data from 16,686 NHANES participants (1999–2010) linked with mortality records were analyzed over a median follow-up of 107 months, during which 3,366 total deaths and 674 CVD deaths occurred. A total of 658 participants had taken glucosamine/chondroitin for a year or longer. In multivariable-adjusted models controlling for age, sex, race, education, smoking status, and physical activity, regular use was associated with reduced all-cause mortality (HR = 0.73; 95% CI, 0.57-0.93) and reduced CVD mortality (HR = 0.42; 95% CI, 0.23-0.75).

Shows an association, not proof of cause and effect.

Study type
Prospective cohort study
Who was studied
16,686 US adults from NHANES (1999–2010)
What was measured
All-cause mortality and cardiovascular disease (CVD) mortality

THE PAPER

Glucosamine/Chondroitin and Mortality in a US NHANES Cohort.

King DE, Xiang J. J Am Board Fam Med, 2020.

PubMed 33219063 ↗DOI 10.3122/jabfm.2020.06.200110 ↗

Heart & arteries

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.